| Dr Thomas J Matzke, | |
|
4656 40th Ave S, Fargo, ND 58104-4397 | |
| (701) 234-8860 | |
| Not Available |
| Full Name | Dr Thomas J Matzke |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 23 Years |
| Location | 4656 40th Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639121304 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 45261 (Minnesota) | Secondary |
| 207N00000X | Dermatology | 10119 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Ellipse Technologies, Inc. announced today it has received CE Mark (Conformité Européenne) for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is for the treatment of spinal scoliosis in young children and teenagers. The CE Mark allows the Company to market the MAGEC System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
Children who were resuscitated at birth have increased risk of low intelligence quotient (IQ) at age eight years, even if they were apparently healthy in the 28 days (neonatal period) following birth.
As the U.S. moves forward with health reform, health care purchasers are working to eliminate waste, overuse, and misuse in the health care system at the point of care. To that end, several of the nation's foremost quality and measurement organizations – Bridges to Excellence (BTE), the Leapfrog Group, and PROMETHEUS Payment® – announced their support of eValue8™, a program of the National Business Coalition on Health (NBCH).
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company's last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.
› Verified 5 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Ellipse Technologies, Inc. announced today it has received CE Mark (Conformité Européenne) for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is for the treatment of spinal scoliosis in young children and teenagers. The CE Mark allows the Company to market the MAGEC System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
Children who were resuscitated at birth have increased risk of low intelligence quotient (IQ) at age eight years, even if they were apparently healthy in the 28 days (neonatal period) following birth.
As the U.S. moves forward with health reform, health care purchasers are working to eliminate waste, overuse, and misuse in the health care system at the point of care. To that end, several of the nation's foremost quality and measurement organizations – Bridges to Excellence (BTE), the Leapfrog Group, and PROMETHEUS Payment® – announced their support of eValue8™, a program of the National Business Coalition on Health (NBCH).
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company's last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.
› Verified 5 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Ellipse Technologies, Inc. announced today it has received CE Mark (Conformité Européenne) for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is for the treatment of spinal scoliosis in young children and teenagers. The CE Mark allows the Company to market the MAGEC System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
Children who were resuscitated at birth have increased risk of low intelligence quotient (IQ) at age eight years, even if they were apparently healthy in the 28 days (neonatal period) following birth.
As the U.S. moves forward with health reform, health care purchasers are working to eliminate waste, overuse, and misuse in the health care system at the point of care. To that end, several of the nation's foremost quality and measurement organizations – Bridges to Excellence (BTE), the Leapfrog Group, and PROMETHEUS Payment® – announced their support of eValue8™, a program of the National Business Coalition on Health (NBCH).
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company's last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas J Matzke, 4656 40th Ave S, Fargo, ND 58104-4397 Ph: (701) 234-8860 | Dr Thomas J Matzke, 4656 40th Ave S, Fargo, ND 58104-4397 Ph: (701) 234-8860 |
News Archive
Ellipse Technologies, Inc. announced today it has received CE Mark (Conformité Européenne) for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is for the treatment of spinal scoliosis in young children and teenagers. The CE Mark allows the Company to market the MAGEC System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
Children who were resuscitated at birth have increased risk of low intelligence quotient (IQ) at age eight years, even if they were apparently healthy in the 28 days (neonatal period) following birth.
As the U.S. moves forward with health reform, health care purchasers are working to eliminate waste, overuse, and misuse in the health care system at the point of care. To that end, several of the nation's foremost quality and measurement organizations – Bridges to Excellence (BTE), the Leapfrog Group, and PROMETHEUS Payment® – announced their support of eValue8™, a program of the National Business Coalition on Health (NBCH).
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company's last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.
› Verified 5 days ago
Dong Kim, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1702 University Dr S, Fargo, ND 58103 Phone: 701-364-3300 | |
Mrs. Rachel C Ness, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3173 43rd Street S Ste A, Fargo, ND 58104 Phone: 701-478-8780 Fax: 701-478-8781 | |
Kimberly Rae Kelly, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1702 University Dr S, Fargo, ND 58103 Phone: 701-364-3300 Fax: 701-364-8906 | |
David B Flach, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4656 40th Ave S, Fargo, ND 58104 Phone: 701-234-8860 Fax: 701-234-8924 | |
Christopher Ryan Cunningham, MD Dermatology Medicare: Medicare Enrolled Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 701-234-2000 | |
Amanda Beehler, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1702 University Dr S, Fargo, ND 58103 Phone: 701-364-3300 Fax: 701-364-8906 | |
Dr. Joanne Ruth Montgomery, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4656 40th Ave S, Fargo, ND 58104 Phone: 701-234-8860 |